KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Repligen (RGEN) EBIT (2016 - 2025)

Repligen (RGEN) has disclosed EBIT for 16 consecutive years, with -$24.2 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 33.7% to -$24.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.1 million, a 137.31% increase, with the full-year FY2025 number at $13.1 million, up 137.31% from a year prior.
  • EBIT was -$24.2 million for Q4 2025 at Repligen, down from $16.8 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $63.2 million in Q2 2022 to a low of -$129.8 million in Q4 2022.
  • A 5-year average of $2.5 million and a median of $10.2 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: plummeted 266.96% in 2024, then surged 314.82% in 2025.
  • Repligen's EBIT stood at -$97.6 million in 2021, then crashed by 33.05% to -$129.8 million in 2022, then surged by 66.45% to -$43.6 million in 2023, then rose by 16.19% to -$36.5 million in 2024, then soared by 33.7% to -$24.2 million in 2025.
  • Per Business Quant, the three most recent readings for RGEN's EBIT are -$24.2 million (Q4 2025), $16.8 million (Q3 2025), and $13.9 million (Q2 2025).